MEP28908A - Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same - Google Patents

Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same

Info

Publication number
MEP28908A
MEP28908A MEP-289/08A MEP28908A MEP28908A ME P28908 A MEP28908 A ME P28908A ME P28908 A MEP28908 A ME P28908A ME P28908 A MEP28908 A ME P28908A
Authority
ME
Montenegro
Prior art keywords
medicament
pentafluorosulfanyl
benzoylguanidine
utilization
production
Prior art date
Application number
MEP-289/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Heinz-Werner Kleemann
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MEP28908A publication Critical patent/MEP28908A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MEP-289/08A 2002-05-18 2003-05-05 Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same MEP28908A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10222192A DE10222192A1 (de) 2002-05-18 2002-05-18 Pentafluorsulfuranyl-benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
PCT/EP2003/004669 WO2003097591A1 (de) 2002-05-18 2003-05-05 Pentafluorsulfanyl-benzoylguanidine, verfahren zu ihrer hertellung, ihre verwendung als medikament oder diagnostikum sowie sie enthaltendes medikament

Publications (1)

Publication Number Publication Date
MEP28908A true MEP28908A (en) 2010-10-10

Family

ID=29285565

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-289/08A MEP28908A (en) 2002-05-18 2003-05-05 Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same

Country Status (29)

Country Link
EP (1) EP1509498B1 (pl)
JP (1) JP4383341B2 (pl)
KR (1) KR100977676B1 (pl)
CN (1) CN100506791C (pl)
AR (1) AR040034A1 (pl)
AT (1) ATE343563T1 (pl)
AU (1) AU2003242531B2 (pl)
BR (1) BR0311128A (pl)
CA (1) CA2486336C (pl)
CY (1) CY1105867T1 (pl)
DE (2) DE10222192A1 (pl)
DK (1) DK1509498T3 (pl)
ES (1) ES2274264T3 (pl)
HK (1) HK1076095A1 (pl)
HR (1) HRP20041078B1 (pl)
IL (2) IL165213A0 (pl)
MA (1) MA27277A1 (pl)
ME (1) MEP28908A (pl)
MX (1) MXPA04011497A (pl)
MY (1) MY139310A (pl)
NO (1) NO333288B1 (pl)
PE (1) PE20040452A1 (pl)
PL (1) PL209700B1 (pl)
PT (1) PT1509498E (pl)
RS (1) RS50772B (pl)
RU (1) RU2315752C2 (pl)
TW (1) TWI281467B (pl)
WO (1) WO2003097591A1 (pl)
ZA (1) ZA200408886B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501440B2 (en) 2003-03-07 2009-03-10 Sanofi-Aventis Deutschland Gmbh Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
DE10338554A1 (de) * 2003-08-22 2005-03-31 Aventis Pharma Deutschland Gmbh Pentafluorosulfanylphenyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE10353204A1 (de) * 2003-11-13 2005-06-16 Aventis Pharma Deutschland Gmbh Verfahren zur Herstellung von 4-Pentafluorsulfanyl-benzoylguanidinen
OA13285A (en) * 2003-11-13 2007-01-31 Sanofi Aventis Deutschland Pentafluorosulfanyl benzoylguanidines, method for their production, their use as medicaments or diagnostic agents and medicament containing the same.
DE10353205A1 (de) * 2003-11-13 2005-06-16 Aventis Pharma Deutschland Gmbh Ortho-substituierte Pentafluorsulfuranyl-Benzole, Verfahren zu ihrer Herstellung sowie ihre Verwendung als wertvolle Synthese-Zwischenstufen
DE102004043938A1 (de) * 2004-09-11 2006-03-30 Sanofi-Aventis Deutschland Gmbh Pentafluorosulfanylphenyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE102004043937A1 (de) * 2004-09-11 2006-03-30 Sanofi-Aventis Deutschland Gmbh Ortho-substituierte Pentafluorsulfuranyl-Benzole, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Synthese-Zwischenstufen
JP4592819B2 (ja) * 2007-02-09 2010-12-08 ファイザー・リミテッド 抗寄生虫剤
UA105354C2 (uk) * 2007-03-23 2014-05-12 Юби Индастриз, Лтд. Спосіб одержання пентафторидів арилсірки
WO2009028514A1 (ja) * 2007-08-28 2009-03-05 Ube Industries, Ltd. ペンタフルオロスルファニルベンゼン化合物の製造方法、及び新規なペンタフルオロスルファニルベンゼン化合物
JP5439745B2 (ja) * 2008-05-27 2014-03-12 宇部興産株式会社 ハロゲノメチルペンタフルオロスルファニルベンゼン化合物及びその製造方法
JP6124015B2 (ja) * 2011-12-06 2017-05-10 宇部興産株式会社 ペンタフルオロスルファニル安息香酸の製造方法
CN108003034B (zh) * 2017-12-26 2020-07-03 金凯(辽宁)化工有限公司 一种2-甲基-5-氨基三氟甲苯的制备方法
RU2765117C2 (ru) * 2019-09-24 2022-01-25 Федеральное государственное автономное образовательное учреждение высшего образования "Уральский федеральный университет имени первого Президента России Б.Н. Ельцина" Применение натриевой соли диэтилового эфира 4-оксо-1,4-дигидропиразоло[5,1-с]-1,2,4-триазин-3,8-дикарбоновой кислоты, моногидрата в качестве средства лечения и профилактики поздних осложнений сахарного диабета

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4417004A1 (de) * 1994-05-13 1995-11-16 Hoechst Ag Perfluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19517848A1 (de) * 1995-05-16 1996-11-21 Merck Patent Gmbh Fluorhaltige Benzoylguanidine
DE19526381A1 (de) * 1995-07-19 1997-01-23 Hoechst Ag 4-Fluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9606015D0 (en) * 1996-03-22 1996-05-22 Rhone Poulenc Agriculture New herbicides

Also Published As

Publication number Publication date
CA2486336C (en) 2011-06-21
BR0311128A (pt) 2005-03-08
RS50772B (sr) 2010-08-31
JP2005526138A (ja) 2005-09-02
CN100506791C (zh) 2009-07-01
NO333288B1 (no) 2013-04-29
PL209700B1 (pl) 2011-10-31
RU2004137115A (ru) 2005-05-27
IL165213A0 (en) 2005-12-18
PE20040452A1 (es) 2004-08-18
HRP20041078B1 (hr) 2013-02-28
WO2003097591A1 (de) 2003-11-27
NO20045447L (no) 2004-12-14
TW200407290A (en) 2004-05-16
AU2003242531A1 (en) 2003-12-02
RS99004A (en) 2007-04-10
ES2274264T3 (es) 2007-05-16
KR20040111635A (ko) 2004-12-31
IL165213A (en) 2009-05-04
CN1653044A (zh) 2005-08-10
RU2315752C2 (ru) 2008-01-27
MY139310A (en) 2009-09-30
CY1105867T1 (el) 2011-02-02
MXPA04011497A (es) 2005-02-14
DE50305498D1 (de) 2006-12-07
CA2486336A1 (en) 2003-11-27
AU2003242531B2 (en) 2008-07-31
EP1509498B1 (de) 2006-10-25
PL371784A1 (pl) 2005-06-27
EP1509498A1 (de) 2005-03-02
HK1076095A1 (en) 2006-01-06
PT1509498E (pt) 2007-01-31
AR040034A1 (es) 2005-03-09
ZA200408886B (en) 2006-01-25
DE10222192A1 (de) 2003-11-27
MA27277A1 (fr) 2005-04-01
DK1509498T3 (da) 2007-02-26
ATE343563T1 (de) 2006-11-15
HRP20041078A2 (en) 2005-04-30
TWI281467B (en) 2007-05-21
KR100977676B1 (ko) 2010-08-25
JP4383341B2 (ja) 2009-12-16

Similar Documents

Publication Publication Date Title
MEP28908A (en) Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same
BR0312134A (pt) Benzoilguanidinas derivadas de cicloalquilas fluoradas e seu emprego como medicamento
CY1105115T1 (el) Παραγωγα ν-((3-οξο-2,3-διυδρο-1η-ισοϊνδολ-1-υλ)ακετυλ)γουανιδινης ως nhe1-αναστολεις για την θepαπεια του εμφραγματος και της στηθαγχης
EA200500312A1 (ru) Новые спироконденсированные хиназолиноны и их применение в качестве ингибиторов фосфодиэстераз
NZ592741A (en) Thiochromene derivatives as hif hydroxylase inhibitors
BR9507995A (pt) Composto uso do composto formulação farmacêutica intermediário e processos para a preparação de um composto e de intermediário e para tratamento de uma condição em que existe uma vantagem em inibir a produção de no a partir de l-arginina pela ação de no sintase
NO20065719L (no) I det vesentlige rene 2-{[2-(2-metylamino-pyrimidin-4-yl)-1H-indol-5-karbonyl]-amlno}-3-(fenylpyridin-2-yl-amino)-propionsyre som en IkB kinaseinhibitor.
WO2004007478A3 (en) Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, process for their preparation and their pharmaceutical use
NO20082005L (no) Syntese av renininhibitorer omfattende en cyklotilfoyelsesreaksjon
ECSP066563A (es) Pentafluorosulfanil-benzoilguanidinas, método para su producción, su uso como medicamentos o agentes de diagnóstico, y medicamento que las contiene
BRPI0406893A (pt) Derivados de acilaminotiazol, a respectiva preparação e a respectiva utilização como inibidores da produção do peptìdeo betaamilóide
UY28358A1 (es) Derivados de 3-(guanidinocarbonil)heterociclos, procedimiento de preparación y compuestos intermedios de este procedimiento, su uso como medicamentos, y composiciones farmaceuticas que los incluyen.
AR026179A1 (es) Benzoilguanidinas heterociclicamente sustituidas, procedimiento para su preparacion, su empleo como medicamentos o medios de diagnostico asi como los medicamentos que las contienen
BR0314714A (pt) Compostos para o tratamento da doença de alzheimer
Luo et al. Synthesis and biological evaluation of Arylthiourea derivatives with antitubercular activity
BRPI0510704A (pt) tienopiridazinas como inibidores de ikk
BRPI0413798A (pt) benzoilguanidinas substituìdas por pentafluorsulfanilfenila, processo para sua preparação, seu emprego como medicamento ou diagnóstico, assim como medicamento contendo-as
TW200621687A (en) Pentafluorosulfanylphenyl-substituted benzoylguanidines, processes for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
BR0307495A (pt) Diidro-tia-fenantreno-carbonil-guanidinas, processo para sua preparação, seu uso como medicamento ou agente de diagnóstico
UA88693C2 (en) Sulfonylamino(thio)carbonyl compounds
BR0302902A (pt) Processo para a preparação de ácido 1- (mercaptometil) - ciclopropanoacético
NO964905L (no) Substituerte benzendikarboksylsyre-diguanidider, fremgangsmåte for deres fremstilling, deres anvendelse som medikament eller diagnostikum samt medikament inneholdende forbindelsen
TH77463A (th) อนุพันธ์ของ 3-กัวนิดิโนคาร์โบนิล-1-เฮเทอโรแอริล-พีร์โรล, กระบวนการเตรียมและสารมัธยันตร์ของกระบวนการนี้, การใช้สารดังกล่าวเป็นยา และสารผสมทางเภสัชกรรมที่ประกอบรวมด้วยสารดังกล่าว
TH154759A (th) สารประกอบเฮตเทอโรไซคลิคอิ่มตัวที่มีไนโตรเจน
TH102713B (th) สารยับยั้งไซคลิค 11-เบตา ไฮดรอกซิสเตอรอยด์ ดีไฮโดรจีเนสประเภท i